TR201714725A1 - Beta-2 agoni̇sti̇ ve anti̇koli̇nerji̇k i̇çeren kuru toz formülasyonu - Google Patents

Beta-2 agoni̇sti̇ ve anti̇koli̇nerji̇k i̇çeren kuru toz formülasyonu Download PDF

Info

Publication number
TR201714725A1
TR201714725A1 TR2017/14725A TR201714725A TR201714725A1 TR 201714725 A1 TR201714725 A1 TR 201714725A1 TR 2017/14725 A TR2017/14725 A TR 2017/14725A TR 201714725 A TR201714725 A TR 201714725A TR 201714725 A1 TR201714725 A1 TR 201714725A1
Authority
TR
Turkey
Prior art keywords
dry powder
anticolinergic
agonist
beta
powder formulation
Prior art date
Application number
TR2017/14725A
Other languages
English (en)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Neutec Ar Ge Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutec Ar Ge Sanayi Ve Ticaret Anonim Sirketi filed Critical Neutec Ar Ge Sanayi Ve Ticaret Anonim Sirketi
Priority to TR2017/14725A priority Critical patent/TR201714725A1/tr
Priority to TR2017/16235A priority patent/TR201716235A2/tr
Priority to TR2017/16233A priority patent/TR201716233A2/tr
Publication of TR201714725A1 publication Critical patent/TR201714725A1/tr

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Mevcut buluş, solunum yolu rahatsızlıklarında kullanılmak üzere, formoterol ve tiotropiumdan oluşan, kuru toz formundaki farmasötik formülasyonlara ilişkindir.
TR2017/14725A 2017-09-30 2017-09-30 Beta-2 agoni̇sti̇ ve anti̇koli̇nerji̇k i̇çeren kuru toz formülasyonu TR201714725A1 (tr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TR2017/14725A TR201714725A1 (tr) 2017-09-30 2017-09-30 Beta-2 agoni̇sti̇ ve anti̇koli̇nerji̇k i̇çeren kuru toz formülasyonu
TR2017/16235A TR201716235A2 (tr) 2017-09-30 2017-10-20 Solunum Yolları Hastalıklarının Tedavisi İçin Birden Fazla Etken Madde İçeren Farmasötik Bileşim
TR2017/16233A TR201716233A2 (tr) 2017-09-30 2017-10-20 Solunum yolları hastalıklarının tedavisi için birden fazla etken madde içeren farmasötik bileşim.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2017/14725A TR201714725A1 (tr) 2017-09-30 2017-09-30 Beta-2 agoni̇sti̇ ve anti̇koli̇nerji̇k i̇çeren kuru toz formülasyonu

Publications (1)

Publication Number Publication Date
TR201714725A1 true TR201714725A1 (tr) 2019-04-22

Family

ID=67981805

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2017/14725A TR201714725A1 (tr) 2017-09-30 2017-09-30 Beta-2 agoni̇sti̇ ve anti̇koli̇nerji̇k i̇çeren kuru toz formülasyonu

Country Status (1)

Country Link
TR (1) TR201714725A1 (tr)

Similar Documents

Publication Publication Date Title
CY1120684T1 (el) Σκευασμα ξηρης σκονης που περιλαμβανει ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο για χορηγηση δια εισπνοης
MA41496A (fr) Compositions pharmaceutiques comprenant la n-(3,5-diméthoxyphényl)-n'-(1-méthyléthyl)-n-[3-(1-méthyl-1h-pyrazol-4-yl)quinoxalin-6-yl]éthane-1,2-diamine
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
MY176176A (en) Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
CY1124490T1 (el) Μια διεργασια για την παρασκευη ενος σκευασματος ξηρης σκονης που περιλαμβανει ενα αντιχολινεργικο, ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο
CO2019008103A2 (es) Composiciones farmacéuticas para terapia de combinación
IN2013MU03583A (tr)
CL2017000394A1 (es) Composición que contiene cineol para la administración nasal
TR201000681A2 (tr) İnhalasyon yoluyla alınan kuru toz formülasyonları.
MX2015015132A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
BR112019001134A2 (pt) uso de lactama e composição farmacêutica
PH12018502139A1 (en) Phosphaplatin liquid formulations
TR201714725A1 (tr) Beta-2 agoni̇sti̇ ve anti̇koli̇nerji̇k i̇çeren kuru toz formülasyonu
IT201700025738A1 (it) Composizione farmaceutica comprendente resveratrolo e polimixine per uso come agente antibatterico
TR201714728A1 (tr) Beta-2 Agonist ve Kortikosteroid içeren kuru toz formülasyonu.
MX345263B (es) Formulación de pexiganan estable.
TR201714893A1 (tr) Beta-2 Agonisti ve Kortikosteroid içeren kuru toz bileşimi.
TR201716207A2 (tr) Vilanterol ve umeklidinyum içeren farmasötik formülasyonlar.
TR201716155A1 (tr) Bir beta-2 agonisti ile birlikte bir kortikosteroid içeren farmasötik formülasyon.
EP3210614A4 (en) Composition containing thymosin beta 4, and pharmaceutical formulation comprising same
PH12015502029A1 (en) Phenylephrine resinate particles and use thereof in pharmaceutical formulations
SG11201507651XA (en) Fine dry particulate resveratrol active agent compositions and topical formulations including the same
TR201716201A2 (tr) Beta-2 agonisti içeren kuru toz formülasyonu.
TR200907915A2 (tr) Kuru toz formunda farmasötik bileşim.